NIMG-56. USING RADIOMIC FEATURES FROM DAILY MAGNETIC RESONANCE IMAGING TO PREDICT RESPONSE TO RADIATION THERAPY IN GLIOBLASTOMA PATIENTS: A PILOT STUDY

Abstract

Abstract A dilemma in treating glioblastoma is that MRI after chemotherapy and radiation therapy (chemoRT) shows areas of presumed tumor growth in up to 50% of patients. These areas can represent true progression (TP), tumor growth with tumors non-responsive to treatment, or pseudoprogression (PP), edema and tumor necrosis with favorable treatment response. On imaging, TP and PP are usually not discernable. Patients in this study undergo six weeks of chemoRT on a combination MRI/RT device, receiving daily MRIs. The goal of this study is to explore the correlation of radiomics features with progression. The tumor lesion and surrounding areas of growth/edema were manually outlined as regions of interest (ROIs) for each daily T2-weighted MRI scan. The ROIs were used to calculate texture features: statistical features based on the gray-level co-occurrence matrix (GLCM), the gray-level zone size matrix (GLZSM), the gray-level run length matrix (GLRLM), and the neighborhood gray-tone difference matrix (NGTDM). Each of these matrix classes describe the probability of spatial relationships of gray levels occurring within the ROI. Daily texture features were averaged per week of treatment for each patient. Patient response was retrospectively defined as no progression (NP), TP, or PP. A Kruskal-Wallis test was performed to identify texture features that correlated most strongly with patient response. Forty texture features were calculated for 12 patients (19 treated, 7 excluded due to no T2 lesion or progression status unknown, 6 NP, 3 TP, 3 PP). There was a trend of more texture features correlating significantly with response in weeks 4-6 of treatment, compared to weeks 1-3. A particular texture feature, GLSZM Small Zone Low Gray-Level Emphasis, showed increasing difference between PP and TP over time, with significant difference during week 6 of treatment (p=0.0495). Future directions include correlating early outcomes with greater numbers of patients and daily multiparametric MRI.